The global demand for Late Stage Chronic Kidney Disease Therapeutics was valued at around USD 4.7 Billion in 2019. However, with rising prevalence of chronic kidney disease across the globe, the overall late stage kidney disease therapeutics market is anticipated to surpass USD 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period (2022 to 2032)
| Report Attribute | Details |
|---|---|
| Late Stage Chronic Kidney Disease Therapeutics Market Projected Growth Rate (2022 to 2032) | 11.6% CAGR |
Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide due to its high morbidity and mortality rates. This fatal disease is usually caused by diabetes mellitus, hypertension, obesity, and aging.
Late stage chronic disease is an advanced stage of chronic renal disease where kidneys no longer function or work. This reduces the chances of survival and therefore requires proper treatment approaches including kidney transplant, dialysis and therapeutics. Among these, kidney transplant and dialysis are the only two effective treatments for CKD. However, dialysis is often costly and transplantation is limited by organ shortage. This has brought late stage chronic kidney disease therapeutics market into the spotlight.
Majority of the people with lower socioeconomic status and limited access to treatments are highly dependent on late stage chronic kidney disease therapeutics. These therapeutics can also be used in combination with dialysis.
Late stage chronic kidney disease therapeutics are drugs used for the treatment of late-stage chronic kidney disease induced hyperkalemia, hyperphosphatemia, hyperparathyroidism. Consumption of late stage chronic kidney disease therapeutics help to relieve the symptoms of CKD, delay late stage chronic kidney disease development, and thus enable patients to live longer lives without going through dialysis or transplantation.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Rising prevalence of chronic kidney disease (CKD) worldwide, rising awareness among people regarding the benefits of late stage chronic kidney disease therapeutics, introduction of favorable reimbursement policies for CKD treatment, higher diagnostic rates, and development of new effective therapeutics are some of the major factors expected to boost the growth of late stage chronic kidney disease therapeutics market during the forecast period.
Increasing incidence of chronic kidney disease is perhaps the major factor behind the robust expansion of late stage chronic disease therapeutics market. According to a report published in the Lancet, global prevalence of chronic kidney diseases reached around 700 million in 2017 and the numbers are expected to further surge during the upcoming years.
Similarly, the introduction of new advanced late stage kidney disease therapeutics along with poor access to renal replacement therapy and dialysis in developing countries is expected to favor market growth during the assessment period.
Despite its optimistic stance, the late stage chronic kidney disease therapeutics market is facing various obstacles that are restraining its growth to some extent. Some of these growth restraining factors are the delay in the diagnosis of CKD and increase in the number of kidney transplants.
Similarly, various side effects associated with late stage chronic kidney disease therapeutics is also limiting market growth.
According to Future Market Insights, North America accounted for the largest share of the global late stage chronic kidney disease therapeutics market in 2021 and is projected to grow at the fastest CAGR over the forecast period. Growth in the market is attributable to the rising incidence of chronic kidney disease, availability of favorable reimbursement policies, and heavy presence of leading market players.
Demand for late stage chronic kidney disease therapeutics is particularly high across the United States due to surge in chronic kidney disease cases and easy availability of advanced therapeutics. According to the Centers for Disease Control and Prevention (CDC), around 37 million people in the United States are estimated to have chronic kidney disease.
The Asia Pacific late stage chronic kidney disease therapeutics market is anticipated to grow at a considerable pace during the forecast period between 2022 and 2032, owing to the rising health awareness, growing prevalence of chronic kidney disease, and increasing government initiatives and investments to reduce the burden of chronic kidney disease.
According to the National Kidney Foundation, number of cases of kidney failure is expected to surge rapidly in developing countries, such as China and India, where the number of elderly people is increasing. This will generate lucrative growth prospects within the Asia Pacific late stage chronic kidney disease therapeutics market during the forecast period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Some of the key participants present in the global late stage chronic kidney disease therapeutics market includes Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire, Vifor and ZS Pharma among others.
These leading players are continuously investing in research and development to introduce more effective therapeutics. Besides this, they are partnering and collaborating with dialysis centers to increase their sales and gain a competitive edge in the market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 11.6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Product Type, Indication, End Users, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; APEJ; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Amgen; Deltanoid; AbbVie; Sanofi; Ardelyx; AstraZeneca; Kyowa Hakko Kirin; Genzyme, Keryx; Spectrum; Mitsubishi Tanabe; OPKO Health; Relypsa; Shield Therapeutics; Shire; Vifor; ZS Pharma |
| Customization | Available Upon Request |
FMI projects the global late stage chronic kidney disease therapeutics market to expand at a stupendous CAGR of around 11.6% through 2032.
North America is forecast to remain the most lucrative market for late stage chronic kidney disease therapeutics during the assessment period.
Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, and Spectrum are some prominent late stage chronic kidney disease therapeutics manufacturers
| Estimated Size, 2024 | USD 42.1 billion |
|---|---|
| Projected Size, 2034 | USD 117.4 billion |
| Value-based CAGR (2024 to 2034) | 10.8% |
| Estimated Market Size (2024E) | USD 37.5 billion |
|---|---|
| Projected Market Value (2034F) | USD 112.8 billion |
| Value-based CAGR (2024 to 2034) | 11.7% |
| Market Value for 2023 | USD 15,246.7 million |
|---|---|
| Projected Market Value for 2033 | USD 30,318.5 million |
| Value-based CAGR of Market for 2023 to 2033 | 7.1% |
Explore Therapy Area Insights
View Reports
Late Stage Chronic Kidney Disease Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
